Clinical relevance of circulating angiogenic cells in patients with ischemic stroke.

Biomarkers Circulating angiogenic cells Colony forming cells Endothelial progenitor cells Functionality Gene Ischemic stroke Late outgrowth endothelial cells

Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
21 03 2022
Historique:
received: 08 10 2021
accepted: 12 12 2021
entrez: 22 3 2022
pubmed: 23 3 2022
medline: 16 4 2022
Statut: epublish

Résumé

Endothelial progenitor cells (EPCs) are circulating angiogenic cells with endothelial features associated with risk for stroke. We aimed to delve into their functional characteristics. EPCs were isolated and cultured from Ischemic Stroke (IS) patients and predictors of their variance evaluated. This is a single-center observational study evaluating 187 consecutively hospitalized patients with IS. EPCs were isolated from blood samples. The number of circulating angiogenic cells (CACs), colony-forming units (CFU-ECs) and the emergence of late outgrowths endothelial cells (LOECs) were counted. We collected clinical variables and measured the stromal cell-derived factor 1 alpha (SDF1α) serum levels. We also examined the relative telomere length and the expression of osteogenic gene markers in CACs. CACs counts and CFU-ECs colony numbers were positively correlated (rho = 0.41, p < 0.001, n = 187). We found significant differences according to whether thrombolytic treatment was performed in the distribution of CFU-ECs (odds ratio (OR) = 2.5; 95% confidence interval (CI) 1.01-6.35; p = 0.042) and CACs (OR = 4.45; 95% IC 1.2-15.5; p = 0.012). The main determinants of CACs variation were the number of risks factors, thrombolysis treatment, arterial hypertension, LOECs occurrence, and the vascular endothelial growth factor expression, whereas CFU-ECs variations depended on hemoglobin content and the relative reduction in the National Institutes of Health Stroke Scale (NIHSS) criteria. The main predictors of LOECs appearance were thrombolysis and length of hospital stay. Our study supports the relevance of patient risk factors and treatments in the analysis of the functional properties of EPCs.

Sections du résumé

BACKGROUND
Endothelial progenitor cells (EPCs) are circulating angiogenic cells with endothelial features associated with risk for stroke. We aimed to delve into their functional characteristics. EPCs were isolated and cultured from Ischemic Stroke (IS) patients and predictors of their variance evaluated.
METHODS
This is a single-center observational study evaluating 187 consecutively hospitalized patients with IS. EPCs were isolated from blood samples. The number of circulating angiogenic cells (CACs), colony-forming units (CFU-ECs) and the emergence of late outgrowths endothelial cells (LOECs) were counted. We collected clinical variables and measured the stromal cell-derived factor 1 alpha (SDF1α) serum levels. We also examined the relative telomere length and the expression of osteogenic gene markers in CACs.
RESULTS
CACs counts and CFU-ECs colony numbers were positively correlated (rho = 0.41, p < 0.001, n = 187). We found significant differences according to whether thrombolytic treatment was performed in the distribution of CFU-ECs (odds ratio (OR) = 2.5; 95% confidence interval (CI) 1.01-6.35; p = 0.042) and CACs (OR = 4.45; 95% IC 1.2-15.5; p = 0.012). The main determinants of CACs variation were the number of risks factors, thrombolysis treatment, arterial hypertension, LOECs occurrence, and the vascular endothelial growth factor expression, whereas CFU-ECs variations depended on hemoglobin content and the relative reduction in the National Institutes of Health Stroke Scale (NIHSS) criteria. The main predictors of LOECs appearance were thrombolysis and length of hospital stay.
CONCLUSIONS
Our study supports the relevance of patient risk factors and treatments in the analysis of the functional properties of EPCs.

Identifiants

pubmed: 35313809
doi: 10.1186/s12872-021-02421-8
pii: 10.1186/s12872-021-02421-8
pmc: PMC8939119
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

118

Informations de copyright

© 2022. The Author(s).

Références

Stem Cells Transl Med. 2019 Jan;8(1):14-21
pubmed: 30156755
Science. 1997 Feb 14;275(5302):964-7
pubmed: 9020076
Stem Cell Rev Rep. 2021 Jun;17(3):952-967
pubmed: 33170433
Circulation. 2003 Mar 11;107(9):1322-8
pubmed: 12628955
Circulation. 2002 Aug 27;106(9):1133-9
pubmed: 12196341
PLoS One. 2020 Jan 29;15(1):e0226324
pubmed: 31995563
Stem Cells. 2013 Feb;31(2):338-48
pubmed: 23165527
Int J Vasc Med. 2015;2015:674213
pubmed: 26451256
Blood. 2007 Mar 1;109(5):1801-9
pubmed: 17053059
Pharmacol Res. 2019 Jun;144:181-191
pubmed: 31004788
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Angiology. 2015 Aug;66(7):631-7
pubmed: 25115553
Stem Cells Int. 2017;2017:2193432
pubmed: 28900446
PLoS One. 2015 Apr 13;10(4):e0124895
pubmed: 25874380
Acta Physiol (Oxf). 2020 Jan;228(1):e13316
pubmed: 31121082
Atherosclerosis. 2012 Jan;220(1):145-50
pubmed: 22093724
Circ Res. 2011 Jun 24;109(1):20-37
pubmed: 21566217
N Engl J Med. 2003 Feb 13;348(7):593-600
pubmed: 12584367
Stroke. 2012 Dec;43(12):3161-7
pubmed: 23042660
PLoS One. 2011;6(9):e25054
pubmed: 21966411
Stem Cells Int. 2018 Nov 18;2018:9847015
pubmed: 30581475
Neural Regen Res. 2021 Aug;16(8):1483-1489
pubmed: 33433461
Int J Cardiol. 2015;186:305-14
pubmed: 25838182
Nat Med. 2000 Apr;6(4):389-95
pubmed: 10742145
Circ Res. 2001 Jul 6;89(1):E1-7
pubmed: 11440984
J Am Coll Cardiol. 2010 Apr 13;55(15):1553-65
pubmed: 20378071
Circ Res. 2012 Feb 17;110(4):624-37
pubmed: 22343557
J Am Coll Cardiol. 2008 Oct 14;52(16):1314-25
pubmed: 18929243
Int J Stroke. 2009 Aug;4(4):267-73
pubmed: 19689755
Circ Res. 2003 Nov 28;93(11):1023-5
pubmed: 14605020
Nucleic Acids Res. 2009 Feb;37(3):e21
pubmed: 19129229
Am J Hypertens. 2009 Sep;22(9):1014-9
pubmed: 19498340
Int J Mol Sci. 2020 May 03;21(9):
pubmed: 32375269
Eur J Neurol. 2012 Dec;19(12):1539-46
pubmed: 22640405
Mol Med Rep. 2016 Dec;14(6):5528-5534
pubmed: 27840978
Front Neurol. 2018 May 07;9:308
pubmed: 29867722
J Cell Mol Med. 2011 Jun;15(6):1299-309
pubmed: 21418513
Blood. 2004 Nov 1;104(9):2752-60
pubmed: 15226175
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
Semin Neurol. 2018 Apr;38(2):208-211
pubmed: 29791947
Blood Cells Mol Dis. 2016 Oct;61:58-65
pubmed: 27667168
J Cell Physiol. 2014 Jan;229(1):10-6
pubmed: 23794280
Stroke. 2008 May;39(5):1441-7
pubmed: 18356550
J Bone Miner Res. 2015 Jan;30(1):95-105
pubmed: 25130304
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):288-93
pubmed: 14699017
J Biol Chem. 2005 Oct 21;280(42):35760-6
pubmed: 16107333
Circ Res. 2017 Mar 3;120(5):e7-e23
pubmed: 28137917
Stroke. 2005 Jan;36(1):151-3
pubmed: 15576657
J Cell Physiol. 2011 Aug;226(8):2139-49
pubmed: 21520066
Front Physiol. 2012 Feb 20;3:30
pubmed: 22363299
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396

Auteurs

Francisco Rodríguez-Esparragón (F)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain. frodesp@gobiernodecanarias.org.

Laura B Torres-Mata (LB)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.

Juan Carlos López-Fernández (JC)

Department of Neurology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.

Laura Cappiello (L)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.

Jesús M González-Martín (JM)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.

Bernardino Clavo (B)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.
Chronic Pain Unit, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Radiation Oncology Department, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Universitary Institute for Research in Biomedicine and Health (iUIBS), Molecular and Translational Pharmacology Group, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Spanish Group of Clinical Research in Radiation Oncology (GICOR), 28029, Madrid, Spain.
Research Network On Health Services in Chronic Diseases (REDISSEC), Instituto de Salud Carlos III, Madrid, Spain.

Jaime A Serna-Gómez (JA)

Department of Cardiovascular Surgery, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.

Lidia Estupiñán-Quintana (L)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.

Cristina Torres-Ascensión (C)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.

Jesús Villar (J)

Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena S/N, 35019, Las Palmas de Gran Canaria, Spain.
CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Li Ka Shing Knowledge Institute at St Michael's Hospital, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH